Clarity Pharmaceuticals (CU6) Q3 2025 TU earnings summary

Executive summary

• Cash position at 31 March 2025 was $95.1 million, with an additional $11.1 million R&D tax incentive received in April, extending cash runway into H2 2026.

• Strategic refocus on high-priority programs: SAR-bisPSMA for prostate cancer, SARTATE for neuroendocrine tumours, and SAR-Bombesin for breast and prostate cancers.

• Closure of two theranostic trials (CL04 and COMBAT) to optimize resource allocation amid market volatility; no safety concerns prompted these closures.

• Three FDA Fast Track Designations for SAR-bisPSMA, positioning the company strongly in the >$10B PSMA-targeted market.

• Strengthened copper-64 supply chain with new agreements in the US (Nusano) and Australia (UQ), supporting late-stage trials and future commercialization.

Financial highlights

• Net operating cash outflows for the quarter were $15.3 million, down from $18 million in the previous quarter due to timing of clinical trial payments.

• Cash and cash equivalents at quarter end were $95.1 million, with an estimated six quarters of funding available.

• FY2024 R&D Tax Incentive of $11.1 million received post-quarter, further bolstering liquidity.

• No material variances in use of funds compared to capital raise documentation.

• Payments to related parties totaled $625,000 for the quarter, covering director fees and salaries.

Outlook and guidance

• Cash runway expected through H2 2026, supporting ongoing and planned clinical programs.

• Focus on advancing SAR-bisPSMA through Phase II/III trials for both diagnostic and therapeutic prostate cancer indications.

• Anticipated topline data from DISCO (SARTATE in NETs) and SABRE (SAR-Bombesin in prostate cancer) trials in coming months.

• Early commercialisation targeted for diagnostic programs pending positive Phase II/III results.